Tomoko Oh‐hara

4.3k total citations
65 papers, 3.4k citations indexed

About

Tomoko Oh‐hara is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Tomoko Oh‐hara has authored 65 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Molecular Biology, 31 papers in Oncology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Tomoko Oh‐hara's work include Cancer therapeutics and mechanisms (17 papers), Drug Transport and Resistance Mechanisms (10 papers) and Lung Cancer Treatments and Mutations (9 papers). Tomoko Oh‐hara is often cited by papers focused on Cancer therapeutics and mechanisms (17 papers), Drug Transport and Resistance Mechanisms (10 papers) and Lung Cancer Treatments and Mutations (9 papers). Tomoko Oh‐hara collaborates with scholars based in Japan, United States and India. Tomoko Oh‐hara's co-authors include Takashi Tsuruo, T Tsuruo, Naoya Fujita, Mikihiko Naito, Shigeo Sato, Y. Sugimoto, Satomi Tsukahara, T Tatsuta, Ryohei Katayama and Takao Yamori and has published in prestigious journals such as Journal of Biological Chemistry, PLoS ONE and JNCI Journal of the National Cancer Institute.

In The Last Decade

Tomoko Oh‐hara

63 papers receiving 3.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tomoko Oh‐hara Japan	31	2.0k	1.7k	400	364	282	65	3.4k
Volker Gekeler Germany	35	3.0k 1.5×	2.0k 1.2×	264 0.7×	608 1.7×	321 1.1×	88	4.6k
Timothy Madden United States	37	2.1k 1.1×	1.6k 0.9×	368 0.9×	714 2.0×	204 0.7×	108	4.8k
Macus Tien Kuo United States	34	1.9k 1.0×	1.4k 0.8×	320 0.8×	1.1k 2.9×	129 0.5×	55	3.8k
Tyler Lahusen United States	25	1.7k 0.9×	1.3k 0.7×	246 0.6×	375 1.0×	90 0.3×	35	3.2k
Patrick M. Navolanic United States	19	2.3k 1.2×	1.0k 0.6×	371 0.9×	562 1.5×	69 0.2×	23	3.5k
Kazuhiro Katayama Japan	30	1.3k 0.6×	1.4k 0.8×	300 0.8×	310 0.9×	149 0.5×	136	3.3k
Andrew G. Hall United Kingdom	36	2.2k 1.1×	756 0.4×	140 0.3×	400 1.1×	401 1.4×	118	4.0k
Cody J. Peer United States	33	1.8k 0.9×	1.5k 0.9×	559 1.4×	351 1.0×	97 0.3×	156	4.0k
M. Tien Kuo United States	37	2.1k 1.1×	1.4k 0.8×	109 0.3×	579 1.6×	275 1.0×	87	3.6k
Masanori Miwa Japan	14	999 0.5×	2.0k 1.1×	346 0.9×	311 0.9×	112 0.4×	33	3.0k

Countries citing papers authored by Tomoko Oh‐hara

Since Specialization

Citations

This map shows the geographic impact of Tomoko Oh‐hara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomoko Oh‐hara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomoko Oh‐hara more than expected).

Fields of papers citing papers by Tomoko Oh‐hara

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tomoko Oh‐hara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomoko Oh‐hara. The network helps show where Tomoko Oh‐hara may publish in the future.

Co-authorship network of co-authors of Tomoko Oh‐hara

This figure shows the co-authorship network connecting the top 25 collaborators of Tomoko Oh‐hara. A scholar is included among the top collaborators of Tomoko Oh‐hara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tomoko Oh‐hara. Tomoko Oh‐hara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Maruyama, Kohei, Yuki Shimizu, Tomoko Oh‐hara, et al.. (2025). Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization. npj Precision Oncology. 9(1). 4–4. 4 indexed citations

Oh‐hara, Tomoko, et al.. (2024). 3D layered co-culture model enhances Trastuzumab Deruxtecan sensitivity and reveals the combined effect with G007-LK in HER2-positive non-small cell lung cancer. Biochemical and Biophysical Research Communications. 725. 150255–150255. 2 indexed citations

Suzuki, Mai, Ken Uchibori, Tomoko Oh‐hara, et al.. (2024). A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer. npj Precision Oncology. 8(1). 46–46. 5 indexed citations

Shimizu, Yuki, Ai Takemoto, Tomoko Oh‐hara, et al.. (2023). MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF. JCI Insight. 8(24). 5 indexed citations

Shimizu, Yuki, Hiroshi Kawachi, Siew‐Kee Low, et al.. (2022). Acquired resistance to BRAF inhibitors is mediated by BRAF splicing variants in BRAF V600E mutation-positive colorectal neuroendocrine carcinoma. Cancer Letters. 543. 215799–215799. 7 indexed citations

Yoshizawa, Takahiro, Ken Uchibori, Mitsugu Araki, et al.. (2021). Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity. npj Precision Oncology. 5(1). 32–32. 16 indexed citations

Seto, Yosuke, Koutaroh Okada, Ken Uchibori, et al.. (2020). Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non‐small cell lung cancer. Thoracic Cancer. 11(3). 581–587. 27 indexed citations

Okada, Koutaroh, Mitsugu Araki, Biao Ma, et al.. (2019). Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance. EBioMedicine. 41. 105–119. 87 indexed citations

Gong, Bo, Tomoko Oh‐hara, Naoya Fujita, & Ryohei Katayama. (2018). 3D culture system containing gellan gum restores oncogene dependence in ROS1 rearrangements non-small cell lung cancer. Biochemical and Biophysical Research Communications. 501(2). 527–533. 7 indexed citations

10.

Okada, Koutaroh, et al.. (2017). Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers. Molecular Cancer Therapeutics. 16(10). 2130–2143. 84 indexed citations

11.

Katayama, Ryohei, et al.. (2014). Tivantinib (ARQ 197) Exhibits Antitumor Activity by Directly Interacting with Tubulin and Overcomes ABC Transporter–Mediated Drug Resistance. Molecular Cancer Therapeutics. 13(12). 2978–2990. 52 indexed citations

12.

Katayama, Ryohei, Takao Yamori, Jie Qi, et al.. (2013). Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition. Cancer Research. 73(10). 3087–3096. 173 indexed citations

13.

Tanaka, Hiroshi, Yutaka Hoshikawa, Tomoko Oh‐hara, et al.. (2009). PRMT5, a Novel TRAIL Receptor-Binding Protein, Inhibits TRAIL-Induced Apoptosis via Nuclear Factor-κB Activation. Molecular Cancer Research. 7(4). 557–569. 62 indexed citations

14.

Tokuda, Emi, Naoya Fujita, Tomoko Oh‐hara, et al.. (2007). Casein Kinase 2–Interacting Protein-1, a Novel Akt Pleckstrin Homology Domain-Interacting Protein, Down-regulates PI3K/Akt Signaling and Suppresses Tumor Growth In vivo. Cancer Research. 67(20). 9666–9676. 53 indexed citations

15.

Mashima, Tetsuo, Tomoko Oh‐hara, Shigeo Sato, et al.. (2005). p53-Defective Tumors With a Functional Apoptosome-Mediated Pathway: A New Therapeutic Target. JNCI Journal of the National Cancer Institute. 97(10). 765–777. 98 indexed citations

16.

Nakagawa, Takumi, Naoya Fujita, Tomoko Oh‐hara, et al.. (1999). Interleukin-1? induces cyclooxygenase-2 expression in bone-derived endothelial cells. Journal of Cellular Physiology. 179(2). 226–232. 8 indexed citations

17.

Seimiya, Hiroyuki, et al.. (1999). Hypoxia Up-Regulates Telomerase Activity via Mitogen-Activated Protein Kinase Signaling in Human Solid Tumor Cells. Biochemical and Biophysical Research Communications. 260(2). 365–370. 77 indexed citations

18.

Katagiri, Nobuya, Takuya Shiraishi, Hiroshi Satō, et al.. (1992). Resolution of 9-(c-4,t-5-bishydroxymethylcyclopent-2-en-r-1-yl)-9H-adenine and selective inhibition of human immunodeficiency virus by the (−) enantiomer. Biochemical and Biophysical Research Communications. 184(1). 154–159. 10 indexed citations

19.

Sugimoto, Yoshikazu, et al.. (1990). Detection of 300-kilodalton membrane protein in adriamycin-resistant human tumor cells by a monoclonal antibody MRK18. Biochemical and Biophysical Research Communications. 169(2). 686–691. 4 indexed citations

20.

Hamada, Hirofumi, et al.. (1988). Purification of the Mr 22,000 calcium-binding protein (sorcin) associated with multidrug resistance and its detection with monoclonal antibodies.. PubMed. 48(11). 3173–8. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact